This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CRX-675
Description: CRX-675 interacts with toll-like receptor 4 (TLR4) and is in development for the treatment of seasonal allergic rhinitis.
Deal Structure: CRX-675 was originally developed by Corixa Corporation.
In July 2005, GlaxoSmithKline completed its acquisition of Corixa.
Additional information available to subscribers only: